Almee™ – anxiety in Pulmonary Fibrosis
Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis.
The COMPANION program is conducted in the US and investigates how Almee affects anxiety in patients with pulmonary fibrosis. The pivotal 9-week, randomized, controlled, fully virtual and decentralized clinical investigation includes 250 patients with all forms of pulmonary fibrosis.
People who are interested may visit www.vicorecompanionstudy.com – the COMPANION investigation website – where people living with pulmonary fibrosis can answer a few questions to check eligibility.
Read more about the COMPANION investigation: Clinicaltrials.gov